Humira retained the top spot on the list of the top 20 selling drugs in 2020. The AbbVie Inc.(NYSE:ABBV) mega-blockbuster generated revenue of nearly $20.4 billion last year, according to an article ...

Although AbbVie's blockbuster treatment Humira (adalimumab) will see biosimilar competition this year, the company expects that Rinvoq (upadacitinib) and Skyrizi (risankizumab) will eventually see ...

Despite the threat of competition, both from biosimilars to Humira and new therapies that work through other mechanisms of action, AbbVie says Humira is still number one. Humira (adalimumab) will ...

AbbVie's growth prospects remain strong despite the impending decline in revenue from Humira, thanks to promising alternatives Skyrizi, Rinvoq, and the recently FDA-approved Linzess. The company's ...

Sales of AbbVie’s blockbuster drug Humira peaked at $18.9bn last year and, according to analysts at Evaluate Pharma, the product is expected to generate $15.2bn through to 2024. These figures are ...

Teva’s dream of a smooth summer launch for its Alvotech-partnered Humira biosimilar is in jeopardy after its Icelandic compatriot weathered a second FDA snub in less than a year. Manufacturing ...

Abbott Laboratories said Wednesday that its first-quarter profit fell 6.2 percent because of increased expenses to launch the company’s new rheumatoid arthritis treatment, Humira, a potential ...

Stelara (ustekinumab) and Humira (adalimumab) are prescription drugs used to treat certain autoimmune or inflammatory conditions. Both are injectable biologic medications. This article explains the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Patients with psoriatic arthritis treated ...